SL
Silence Therapeutics plc
SLNCF · OTC
$4.40 +10.00% (+$0.40)
1M -11.11%
Market Cap $623.5M
P/E Ratio -
Div. Yield -
ROE 106.94%
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/B 16.21x
P/S 1,013.82x
EV/EBITDA N/A
Growth
22 /100
Declining Book val. growth 41.33%
Rev. growth 68.27%
FCF growth N/A
Profitability
0 /100
Weak Net margin 9,748.46%
Op. margin 9,439.19%
FCF margin 6,334.92%
Quality
0 /100
Poor ROE 106.94%
ROA 56.34%
Asset turnover 0.01x
Debt
100 /100
Low Current ratio 7.42x
Debt/Equity 0.00x
Net debt/EBITDA N/A
Stability
17 /100
Unstable Rev. volatility 91.22%
EPS volatility 64.32%
Profitable years 0
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na SLNCF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Iain Gladstone Ross
Employees
88
Headquarters
London